NASDAQ:DVAX - Dynavax Technologies Stock Price, News, & Analysis

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company earned $5.77 million during the quarter, compared to analyst estimates of $5.95 million. Dynavax Technologies had a negative net margin of 1,156.11% and a negative return on equity of 190.84%. The company's quarterly revenue was up 3294.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.63) earnings per share. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Dynavax Technologies.

4 brokerages have issued 12-month target prices for Dynavax Technologies' stock. Their predictions range from $13.00 to $30.00. On average, they anticipate Dynavax Technologies' share price to reach $23.6667 in the next year. This suggests a possible upside of 521.2% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

News stories about DVAX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include OrganiGram (OGI), Amphastar Pharmaceuticals (AMPH), Endo International (ENDP), Ra Pharmaceuticals (RARX), ArQule (ARQL), Theravance Biopharma (TBPH), Wave Life Sciences (WVE), ANI Pharmaceuticals (ANIP), ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), Spectrum Pharmaceuticals (SPPI), Principia Biopharma (PRNB), Deciphera Pharmaceuticals (DCPH), Rocket Pharmaceuticals (RCKT) and Homology Medicines (FIXX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), Kite Pharma (KITE), United Continental (UAL), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (5.86%), Chicago Capital LLC (3.98%), Eagle Asset Management Inc. (3.74%), Clearbridge Investments LLC (1.79%), FMR LLC (1.67%) and Edmond DE Rothschild Holding S.A. (0.91%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, DekaBank Deutsche Girozentrale, Gables Capital Management Inc. and Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Dynavax Technologies company stock in the last year include David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

DVAX stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Rhenman & Partners Asset Management AB, Marshall Wace North America L.P., Federated Investors Inc. PA, Assenagon Asset Management S.A., Eagle Asset Management Inc., Edmond DE Rothschild Holding S.A. and Bailard Inc.. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $3.81.

Dynavax Technologies has a market capitalization of $247.88 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]